Purpose: To explore the clinical efficacy and long-term outcomes of accessory hepatic vein (AHV) recanalization as a means of treating hepatic vein (HV)-type Budd-Chiari syndrome (BCS).
Methods: Between January 2011 and December 2018, a total of 46 symptomatic HV-type BCS patients were treated by AHV recanalization in our hospital. The technical and clinical success of this treatment, as well as associated long-term patient prognosis was assessed herein.
Results: The AHV recanalization approach was technically successful in 100% of patients, without any instances of complications associated with the operation. This procedure was 95.7% (44/46) clinically successful and resultant. AHV re-obstruction occurred in 12 patients. The cumulative primary one-, two-, and five-year patency rates were 77.3%, 71.7%, and 71.7%, respectively. The secondary cumulative one-, two-, and five-year patency rates were 97.7, 87.1, and 87.1%, respectively. The five-year patency rates did not differ significantly between patients treated with balloons and stents ( = .674). Based on Cox-regression analysis, younger age was an independent predictor of re-obstruction ( = .005). The cumulative one-, two-, and five-year survival rates were 97.7, 92.2, and 92.2%, respectively.
Conclusions: AHV recanalization is a safe and effective treatment for HV-type BCS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/13645706.2020.1723110 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Accessory hepatic vein recanalization for Budd-Chiari syndrome: a systematic review and meta-analysis.
BMC Gastroenterol
October 2023
Department of Radiology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Background: Budd-Chiari syndrome (BCS) results when the outflow of the hepatic vein (HV) is obstructed. BCS patients exhibiting an accessory HV (AHV) that is dilated but obstructed can achieve significant alleviation of liver congestion after undergoing AHV recanalization. This meta-analysis was developed to explore the clinical efficacy of AHV recanalization in patients with BCS.
View Article and Find Full Text PDFPercutaneous recanalization in hepatic vein-type Budd-Chiari syndrome: hepatic or accessory hepatic vein.
Minim Invasive Ther Allied Technol
February 2023
Department of Interventional Radiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Purpose: This study was designed to assess the clinical efficiency and long-term outcomes of hepatic vein (HV) and accessory hepatic vein (AHV) recanalization in patients with HV-type Budd-Chiari syndrome (BCS).
Material And Methods: A total of 27 patients with HV-type BCS underwent AHV recanalization and 94 patients had HV recanalization at our center from January 2012 to December 2019. The treatment effectiveness and long-term outcomes were compared.
Recanalization of accessory hepatic vein for hepatic vein-type Budd-Chiari syndrome.
Abdom Radiol (NY)
July 2021
Department of Radiology, Nanjing Medical University, Nanjing, Jiangsu, China.
Objective: To evaluate the clinical efficacy and long-term outcomes associated with the treatment of hepatic vein (HV)-type Budd-Chiari syndrome (BCS) via accessory HV (AHV) recanalization.
Methods: In total, 26 HV-type BCS patients underwent AHV recanalization between July 2014 and December 2019 at our hospital, while 73 HV-type BCS patients without compensatory AHV underwent main HV (MHV) recanalization and served as controls in the present study. Short- and long-term clinical outcomes were compared.
Long-term outcomes of interventional treatment for Budd-Chiari syndrome with chronic accessory hepatic vein obstruction.
Eur J Gastroenterol Hepatol
May 2021
Department of Interventional Radiology, The Affiliated Hospital of Xuzhou Medical University.
Objective: Interventional treatment is the main therapy for Budd-Chiari syndrome (BCS) with hepatic vein obstruction. The aim of this study was to investigate the long-term outcomes of endovascular management for BCS with chronic accessory hepatic vein (AHV) obstruction.
Methods: In total, 68 patients with primary BCS who underwent AHV dilation with or without stenting from January 2008 to December 2018 were included in this retrospective study.
Accessory hepatic vein recanalization for hepatic vein-type Budd-Chiari syndrome.
Minim Invasive Ther Allied Technol
August 2021
Department of Radiology, Xuzhou Central Hospital, Xuzhou, China.
Purpose: To explore the clinical efficacy and long-term outcomes of accessory hepatic vein (AHV) recanalization as a means of treating hepatic vein (HV)-type Budd-Chiari syndrome (BCS).
Methods: Between January 2011 and December 2018, a total of 46 symptomatic HV-type BCS patients were treated by AHV recanalization in our hospital. The technical and clinical success of this treatment, as well as associated long-term patient prognosis was assessed herein.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!